menu
    • menu
    [{"orgOrder":0,"company":"Polynoma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Not Applicable"},{"orgOrder":0,"company":"Polynoma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Not Applicable"},{"orgOrder":0,"company":"Polynoma","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"CK Life Sciences","sponsor":"XtalPi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"CK Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CK Life Sciences \/ CK Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"CK Life Sciences \/ CK Life Sciences"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Dogwood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"WEX Pharmaceuticals \/ Wex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"WEX Pharmaceuticals \/ Wex Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by CK Life Sciences

    Menu

    CK Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            WEX Pharmaceuticals

                            Canada arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            WEX Pharmaceuticals

                            Canada arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Dogwood Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Virios Therapeutics And Wex Pharmaceuticals Form Dogwood Therapeutics

                            Details : The combined company will be focused on Halneuron, in Phase 2b for chemotherapy-induced neuropathic pain, IMC-1, poised for Phase 3 for fibromyalgia and IMC-2 to treat Long-COVID sequelae.

                            Brand Name : Halneuron

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Dogwood Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            WEX Pharmaceuticals

                            Canada arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            WEX Pharmaceuticals

                            Canada arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Ha...

                            Details : Halneuron (tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels, being developed for Neuropathic Pain.

                            Brand Name : Halneuron

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2023

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            WEX Pharmaceuticals

                            Canada arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            WEX Pharmaceuticals

                            Canada arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wex Pharmaceuticals Inc. Enrolls the First Patient in the Phase 2b Clinical Trial Evaluating the Efficacy and ...

                            Details : Halneuron (Tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels and/or by blocking ectopic discharges associated with chronic pain.

                            Brand Name : Halneuron

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CK Life Sciences

                            Hong Kong arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            CK Life Sciences

                            Hong Kong arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : XtalPi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            XtalPi and CK Life Sciences to Collaborate in AI-empowered Tumour Vaccine Research And Development, Opening A ...

                            Details : XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 24, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : XtalPi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Polynoma

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Polynoma

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seviprotimut-L

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : U.S. Food and Drug Administration

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polynoma Receives Special Protocol Assessment (SPA) Agreement from the U.S. FDA for a Pivotal Phase 3 Clinical...

                            Details : Seviprotimut-L stimulates humoral and cellular immune response, is in clinical development as a potential adjuvant treatment for patients 60 years and younger with Stage IIB or IIC melanoma.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 11, 2022

                            Lead Product(s) : Seviprotimut-L

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : U.S. Food and Drug Administration

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Polynoma

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Polynoma

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seviprotimut-L

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L

                            Details : U.S. Food and Drug Administration (FDA) has granted Polynoma's application for Fast Track designation of seviprotimut-L, its melanoma cancer vaccine for the adjuvant treatment of stage IIB/IIC melanoma patients post-resection to improve recurrence-free s...

                            Brand Name : POL-103A

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 23, 2020

                            Lead Product(s) : Seviprotimut-L

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Polynoma

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Polynoma

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seviprotimut-L

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polynoma Presenting Final Analysis of MAVIS Phase III Part B1 Data of Its Investigational Melanoma Vaccine, Se...

                            Details : Study data show a durable recurrence-free survival clinical benefit in patients with localized melanoma, supporting the potential use of seviprotimut-L as an adjuvant treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 13, 2020

                            Lead Product(s) : Seviprotimut-L

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth